Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Twenty-eight patients with choriocarcinoma have received the three kinds of combination chemotherapy since 1983 at our department, i.e., MOA consisting of moderate dose methotrexate (MTX), actinomycin-D (Act-D) and vincristine, MEA (moderate dose MTX, Act-D and etoposide) and FA (high dose 5-Fluorouracil and Act-D). The clinical and laboratory data obtained in the 28 patients were summarized as follows; 1. The MOA regimen was administered to 4 patients primarily and to 2 secondarily. All of the 6 patients attained remission, but finally two (33.3%) developed relapse. 2. The MEA regimen was administered to 12 patients primarily and to 12 secondarily. Of the 24 patients, five (20.8%) were found to be resistant to the MEA regimen. Nineteen patients (79.2%) attained remission, but 2 (10.5%) developed recurrence. 3. The FA regimen was attempted in one patient primarily and in 6 secondarily. Although one patient died, the remaining 6 achieved remission and one relapse has been observed in the 6 cases. 4. By applying the above mentioned 3 combination chemotherapy regimens, the overall survival rate was pushed up from 64% to 90% in choriocarcinoma patients. 5. Three patients finally died of the disease but not from the side effects of the combination chemotherapies. The major adverse effects were alopecia, nausea, vomiting and myelosuppression. In particular, serious myelosuppression was caused by the MEA or FA regimen in 5-7% of all chemotherapy courses.
 ...
PMID:[A study of first and second line chemotherapies in gestational choriocarcinoma]. 825 29

Varenicline orally administered nicotine acetylcholine receptor partial agonist is approved by the US FDA and the MEA for use as an aid to smoking cessation therapy. Varenicline is more effective than bupropion but does not reduce weight gain after cessation. The superiority of de varenicline on the nicotine is not demonstrated. Nausea is a frequent adverse effect. The long term safety of varenicline is unknown. The major weapons for smoking cessation are represented by the motivation of the patient and a long term psychotherapy. As to the subject of drugs, varenicline is situated in second position, after the failure of a nicotine substitute.
 ...
PMID:[Varenicline: an aid to smoking cessation therapy]. 1826 11